Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate whether the sodium–glucose cotransporter 2 inhibitor empagliflozin (EMPA) reduces liver fat content (LFC) in recent-onset and metabolically well-controlled type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: Patients with T2D (n = 84) (HbA1c 6.6 ± 0.5% [49 ± 10 mmol/mol], known disease duration 39 ± 27 months) were randomly assigned to 24 weeks of treatment with 25 mg daily EMPA or placebo. The primary end point was the difference of the change in LFC as measured with magnetic resonance methods from 0 (baseline) to 24 weeks between groups. Tissue-specific insulin sensitivity (secondary outcome) was assessed by two-step clamps using an isotope dilution technique. Exploratory analysis comprised circulating surrogate markers of insulin sensitivity and liver function. Statistical comparison was done by ANCOVA adjusted for respective baseline values, age, sex, and BMI. RESULTS: EMPA treatment resulted in a placebo-corrected absolute change of −1.8% (95% CI −3.4, −0.2; P = 0.02) and relative change in LFC of −22% (−36, −7; P = 0.009) from baseline to end of treatment, corresponding to a 2.3-fold greater reduction. Weight loss occurred only with EMPA (placebo-corrected change −2.5 kg [−3.7, −1.4]; P < 0.001), while no placebo-corrected change in tissue-specific insulin sensitivity was observed. EMPA treatment also led to placebo-corrected changes in uric acid (−74 mol/L [−108, −42]; P < 0.001) and high-molecular-weight adiponectin (36% [16, 60]; P < 0.001) levels from 0 to 24 weeks. CONCLUSIONS: EMPA effectively reduces hepatic fat in patients with T2D with excellent glycemic control and short known disease duration. Interestingly, EMPA also decreases circulating uric acid and raises adiponectin levels despite unchanged insulin sensitivity. EMPA could therefore contribute to the early treatment of nonalcoholic fatty liver disease in T2D.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, the amount of weight loss determined the amount of liver lipid reduction for both empagliflozin [98] and canagliflozin [155] in respective RCTs.”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [98]
In the citing paper
“Notably, weight loss-mediated improvement of MASLD-related steatosis did not necessarily depend on normalization of glycemia in RCTs with caloric restriction or sodium-glucose co-transporter 2 inhibitor (SGLT2I) treatment [97][98][99].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [98]
In the citing paper
“whereas both dapagliflozin and empagliflozin were able to reduce liver lipid content in people with type 2 diabetes with (dapagliflozin [153,154]) or both with and without MASLD (empagliflozin [98]).”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [98]
In the citing paper
“Further, in another RCT, empagliflozin led to a placebocorrected 2.3-fold greater reduction in liver lipid content and a 36 % increase in plasma adiponectin levels in people with type 2 diabetes and short diabetes duration, despite unchanged fasting glycemia and tissuespecific insulin sensitivity [4,98].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [98]
In the citing paper
“Trials in people with T2D (not all with MASLD and some excluding high ALT values) have shown a moderate reduction in liver lipid content with empagli fl ozin, 414,415 dapagli fl ozin 416 and licoglifl ozin.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [415]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Missing data: our view of the state of the art
Schafer, J. L., & Graham, J. W. (2002) · Psychological Methods · doi:10.1037/1082-989x.7.2.147 · Cited by 11,638
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
A short questionnaire for the measurement of habitual physical activity in epidemiological studies
Baecke, J., Burema, J., & Frijters, J. (1982) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/36.5.936 · Cited by 3,945
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Szczepaniak, L. S., Nurenberg, P., Leonard, D., Browning, J. D., Reingold, J. S., Grundy, S., Hobbs, H. H., & Dobbins, R. L. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00064.2004 · Cited by 1,562 · cited 1×
“56% [21]) occurred in 5 (20%) of 25 patients in the EMPA group and 2 (8%) of 24 patients in the placebo group at 24 weeks.”
BackgroundTreatment of NAFLD with diet, physical activity and exercise
Romero-Gómez, M., Zelber-Sagi, S., & Trenell, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.016 · Cited by 1,347 · cited 1×
“02) and relative decrease in LFC (222% [236, 27]; P 5 0.”
BackgroundMetabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134
Tilg, H., Moschen, A. R., & Roden, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.147 · Cited by 1,002
Self-citationDapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795
Cited by
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Self-citationCusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments
Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00448-y · Cited by 850
Self-citationMetabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review
Chan, W.-K., Chuah, K.-H., Rajaram, R. B., Lim, L.-L., Ratnasingam, J., & Vethakkan, S. R. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23052 · Cited by 776
Kanwal, F., Shubrook, J. H., Adams, L. A., Pfotenhauer, K., Wai-Sun Wong, V., Wright, E., Abdelmalek, M. F., Harrison, S. A., Loomba, R., Mantzoros, C. S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.049 · Cited by 618
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Ferguson, D., & Finck, B. N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00507-z · Cited by 504
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO) (2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 471
Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities
Opazo-Ríos, L., Mas, S., Marín-Royo, G., Mezzano, S., Gómez-Guerrero, C., Moreno, J. A., & Egido, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072632 · Cited by 363
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Rong, L., Zou, J., Ran, W., Qi, X., Chen, Y., Cui, H., & Guo, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1087260 · Cited by 301
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Pafili, K., & Roden, M. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101122 · Cited by 330
“Several RCTs have reported a decrease in hepatic fat content with empagliflozin [11], dapagliflozin [193,194] and the dual SGLT1/SGLT2i, licogliflozin [188], and some studies with dapagliflozin [195,196] and canagliflozin [197] have revealed no effect (Table 3).”
BackgroundInfluentialSelf-citationNasiri-Ansari, N., Nikolopoulou, C., Papoutsi, K., Kyrou, I., Mantzoros, C. S., Kyriakopoulos, G., Chatzigeorgiou, A., Kalotychou, V., Randeva, M. S., Chatha, K., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020818 · Cited by 297
“, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (γ-GT), triglycerides, hepatic insulin sensitivity indices), or by intrahepatic fat content on CT, MRI and proton-magnetic resonance spectroscopy imaging [6,11].”
BackgroundInsulin resistance and insulin sensitizing agents
Mastrototaro, L., & Roden, M. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154892 · Cited by 254
Self-citationElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Cusi, K., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s004 · Cited by 222
Mantovani, A., Byrne, C. D., & Targher, G. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00261-2 · Cited by 230
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Cusi, K., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s004 · Cited by 205
Taheri, H., Malek, M., Ismail-Beigi, F., Zamani, F., Sohrabi, M., Reza babaei, M., & Khamseh, M. E. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01498-5 · Cited by 188
Negi, C. K., Babica, P., Bajard, L., Bienertova-Vasku, J., & Tarantino, G. (2022) · Metabolism · doi:10.1016/j.metabol.2021.154925 · Cited by 190
Eslam, M., Fan, J.-G., Yu, M.-L., Wong, V. W.-S., Cua, I. H., Liu, C.-J., Tanwandee, T., Gani, R., Seto, W.-K., Alam, S., et al. (2025) · Hepatology International · doi:10.1007/s12072-024-10774-3 · Cited by 170
Chew, N. W. S., Mehta, A., Goh, R. S. J., Zhang, A., Chen, Y., Chong, B., Chew, H. S. J., Shabbir, A., Brown, A., Dimitriadis, G. K., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.070535 · Cited by 167
“66 In trials examining MRI-measured changes in liver triglyceride content, SGLT2 inhibition with dapagliflozin, 67,81 empagliflozin, 82–84 or canagliflozin 85 has been associated with reduction of hepatic steatosis.”
Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review
Cariou, B., Byrne, C. D., Loomba, R., & Sanyal, A. J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14322 · Cited by 168
“ealed a marked decrease in serum UA and a rise in serum high molecular weight adiponectin levels.(140) These effects occurred in the presence of moderate weight loss and despite only minor changes in”
BackgroundInfluentialSGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
Androutsakos, T., Nasiri-Ansari, N., Bakasis, A.-D., Kyrou, I., Efstathopoulos, E., Randeva, H. S., & Kassi, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063107 · Cited by 165
“Kinoshita, T., et al., 2020 [162] Randomized, open label, prospective 98 Dapagliflozin (32) Pioglitazone (33) Glimepiride (33) 28 C/T Improvement of L/S ratio and ALT with pioglitazone and dapagliflozin Takahashi, H., et al., 2021 [168] Randomized, open label, prospective 55 Ipragliflozin (27) SOC, except pioglitazone…”
InfluentialNAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment
Targher, G., Corey, K. E., & Byrne, C. D. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.101215 · Cited by 165
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Huttasch, M., Roden, M., & Kahl, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155937 · Cited by 169
Self-citationGaborit, B., Ancel, P., Abdullah, A. E., Maurice, F., Abdesselam, I., Calen, A., Soghomonian, A., Houssays, M., Varlet, I., Eisinger, M., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01237-2 · Cited by 160
“[50] who reported a significant effect of empagliflozin 25 mg compared to placebo in T2D patients with excellent glycemic control and short disease duration.”
BackgroundElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Cusi, K. J., Ekhlaspour, L., Fleming, T. K., Hilliard, M. E., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc24-s004 · Cited by 250
Metabolic liver disease in diabetes – From mechanisms to clinical trials
Dewidar, B., Kahl, S., Pafili, K., & Roden, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154299 · Cited by 158
“[127] Controlled T2DM with short known disease duration, HbA1c = ~6.”
Self-citationPortincasa, P., Khalil, M., Mahdi, L., Perniola, V., Idone, V., Graziani, A., Baffy, G., & Ciaula, A. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115640 · Cited by 180
“This effect is beneficial to MASLD [272–274].”
Lin, J., Huang, Y., Xu, B., Gu, X., Huang, J., Sun, J., Jia, L., He, J., Huang, C., Wei, X., et al. (2025) · BMJ · doi:10.1136/bmj-2024-083735 · Cited by 167
Arab, J. P., Dirchwolf, M., Álvares-da-Silva, M. R., Barrera, F., Benítez, C., Castellanos-Fernandez, M., Castro-Narro, G., Chavez-Tapia, N., Chiodi, D., Cotrim, H., et al. (2020) · Annals of Hepatology · doi:10.1016/j.aohep.2020.09.006 · Cited by 141
Mantovani, A., Byrne, C. D., Scorletti, E., Mantzoros, C. S., & Targher, G. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.12.007 · Cited by 138
Mantovani, A., Petracca, G., Csermely, A., Beatrice, G., & Targher, G. (2020) · Metabolites · doi:10.3390/metabo11010022 · Cited by 134
“Among these individuals, 414 were randomly assigned to either placebo or reference therapy, whereas 436 were randomly assigned to active treatment with dapagliflozin (n = 6 RCTs [19,22,24,25,27,30]), empagliflozin (n = 3 RCTs [21,26,28]), ipragliflozin (n = 2 RCTs [20,29]) or canagliflozin (n = 1 RCT [23]) in order to…”
BackgroundMethodMetabolic dysfunction-associated steatotic liver disease and the heart
Driessen, S., Francque, S., Anker, S. D., Cabezas, M. C., Grobbee, D. E., Tushuizen, M. E., & Holleboom, A. G. (2023) · Hepatology · doi:10.1097/hep.0000000000000735 · Cited by 151
“[130] Another promising subclass are those regulating glucagon-inhibiting incretins.”
Shen, Y., Cheng, L., Xu, M., Wang, W., Wan, Z., Xiong, H., Guo, W., Cai, M., & Xu, F. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155657 · Cited by 117
Kullmann, S., Hummel, J., Wagner, R. J., Dannecker, C., Vosseler, A., Fritsche, L., Veit, R., Kantartzis, K., Machann, J., Birkenfeld, A. L., et al. (2021) · Diabetes Care · doi:10.2337/dc21-1136 · Cited by 124
“Reduction of liver fat content in response to SGLT2 inhibition was reported to be accompanied by lower EGP in some (33), but not all previous trials (28,34).”
BackgroundResultInfluentialSelf-citationByrne, C. D., Armandi, A., Pellegrinelli, V., Vidal‐Puig, A., & Bugianesi, E. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01045-z · Cited by 136
Duseja, A. K., Singh, S. P., De, A., Madan, K., Rao, P. N., Shukla, A., Choudhuri, G., Saigal, S., Shalimar, S., Arora, A., et al. (2022) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2022.11.014 · Cited by 117
Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges
Kuchay, M. S., Martínez‐Montoro, J. I., Choudhary, N. S., Fernández‐García, J. C., & Ramos‐Molina, B. (2021) · Biomedicines · doi:10.3390/biomedicines9101346 · Cited by 118
Roeb, E., Canbay, A. E., Tacke, F., Bantel, H., Bojunga, J., de Laffolie, J., Demir, M., Denzer, U. W., Geier, A., Hofmann, W. P., et al. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2283 · Cited by 124
Self-citationYoneda, M., Honda, Y., Ogawa, Y., Kessoku, T., Kobayashi, T., Imajo, K., Ozaki, A., Nogami, A., Taguri, M., Yamanaka, T., et al. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001990 · Cited by 99
NAFLD and thyroid function: pathophysiological and therapeutic considerations
Hatziagelaki, E., Paschou, S. A., Schön, M., Psaltopoulou, T., & Roden, M. (2022) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2022.08.001 · Cited by 93
Self-citationBajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s004 · Cited by 133
Galiero, R., Caturano, A., Vetrano, E., Cesaro, A., Rinaldi, L., Salvatore, T., Marfella, R., Sardu, C., Moscarella, E., Gragnano, F., et al. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2203082 · Cited by 98
Management of NAFLD in primary care settings
Wong, V. W. S., Zelber‐Sagi, S., Cusi, K., Carrieri, P., Wright, E., Crespo, J., & Lazarus, J. V. (2022) · Liver International · doi:10.1111/liv.15404 · Cited by 81
Moon, J. S., Hong, J. H., Jung, Y. J., Ferrannini, E., Nauck, M. A., & Lim, S. K. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.03.005 · Cited by 85
Dougherty, J. A., Guirguis, E., & Thornby, K.-A. (2021) · Annals of Pharmacotherapy · doi:10.1177/1060028020935105 · Cited by 75
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies
Genua, I., & Cusi, K. J. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0012 · Cited by 77
SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD
Ala, M. (2021) · Endocrinology · doi:10.1210/endocr/bqab157 · Cited by 75
Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes
Cusi, K. (2020) · Diabetes Care · doi:10.2337/dci19-0064 · Cited by 67
“, 2019 (52) Empagliflozin 84 24 Placebo ↓ 2.”
Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease
Lin, H., Zhang, X., Li, G., Wong, G. L.-H., & Wong, V. W.-S. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00201 · Cited by 85
Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis
Branković, M., Jovanović, I., Dukić, M., Radonjić, T., Oprić, S., Klašnja, S., & Zdravkovic, M. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095146 · Cited by 76
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Wang, D., Liu, J. Y., Zhong, L., Li, S., Zhou, L., Zhang, Q., Li, M., & Xiao, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1045235 · Cited by 73
Michalopoulou, E., Thymis, J., Lampsas, S., Pavlidis, G., Katogiannis, K., Vlachomitros, D., Katsanaki, E., Kostelli, G., Pililis, S., Pliouta, L., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020428 · Cited by 76
“A 2020 study by Kahl et al. involved 84 patients with diabetes who had excellent glycemic control, randomly assigned to either empagliflozin or a placebo [141].”
SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8+ T cell activation
Liu, W., You, D., Lin, J., Zou, H., Zhang, L., Luo, S., Yuan, Y., Wang, Z., Qi, J., Wang, W., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.08.005 · Cited by 61
Shi, M., Zhang, H., Wang, W., Zhang, X., Liu, J., Wang, Q., Wang, Y., Zhang, C., Guo, X., Qiao, Q., et al. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108610 · Cited by 67
Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease
Budd, J. T., & Cusi, K. J. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01349-1 · Cited by 61
Pradhan, R., Yin, H., Yu, O. H. Y., & Azoulay, L. (2022) · Diabetes Care · doi:10.2337/dc21-1953 · Cited by 62
“Similarly, SGLT-2 inhibitors compared with placebo reduced hepatic fat in RCTs among patients with type 2 diabetes and NAFLD (11,12).”
BackgroundDiabetes as a risk factor for MASH progression
Gancheva, S., Roden, M., & Castéra, L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111846 · Cited by 65
Self-citationBea, S., Ko, H. Y., Bae, J. H., Cho, Y. M., Chang, Y., Ryu, S., Byrne, C. D., & Shin, J. (2024) · Gut · doi:10.1136/gutjnl-2024-332687 · Cited by 68
“16 44 Lastly, although demonstrated solely in animal studies, evidence suggests that inhibiting SGLT-2 with dapagli-flozin directly reduces hepatic steatosis by activating 5' AMP-activated protein kinase.”
Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis
Radlinger, B., Ress, C., Folie, S., Salzmann, K., Lechuga, A., Weiss, B., Salvenmoser, W., Graber, M., Hirsch, J., Holfeld, J., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05851-x · Cited by 66
Self-citationCheung, K. S., Ng, H. Y., Hui, R. W. H., Lam, L. K., Mak, L., Ho, Y. C., Tan, J. T., Chan, E. W., Seto, W., Yuen, M., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000855 · Cited by 62
“| 923 http://links.lww.com/HEP/I345), only 1 [41] of the 3 dapagliflozin trials [38,39,41] and all 2 empagliflozin [20,21] and 1 canagliflozin trials [40] showed beneficial effects of SGLT2 inhibitors.”
InfluentialGries, J. J., Lazarus, J. V., Brennan, P., Siddiqui, M. S., Targher, G., Lang, C. C., Virani, S. S., Lavie, C. J., Isaacs, S. D., Arab, J. P., et al. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00310-8 · Cited by 68
Harreiter, J., Just, I., Leutner, M., Bastian, M., Brath, H., Schelkshorn, C., Klepochova, R., Krššák, M., & Kautzky‐Willer, A. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14319 · Cited by 53
Huang, C.-C., Chou, C., Chen, W., Yang, J., Lee, W., Chen, J., Lee, C., & Li, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212408 · Cited by 58
“have demonstrated that empagliflozin can decrease hepatic steatosis in patients with type 2 DM [34].”
BackgroundHiruma, S., Shigiyama, F., & Kumashiro, N. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15006 · Cited by 57
Apostolopoulou, M., Mastrototaro, L., Hartwig, S., Pesta, D. H., Straßburger, K., Filippo, E. D., Jeleník, T., Karusheva, Y., Gancheva, S., Markgraf, D. F., et al. (2021) · Science Advances · doi:10.1126/sciadv.abi9551 · Cited by 54
Self-citationMetabolic syndrome and its association with nonalcoholic steatohepatitis
Bril, F., Sanyal, A., & Cusi, K. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.002 · Cited by 52
Cariou, B. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14651 · Cited by 62
Cusi, K. (2020) · Liver International · doi:10.1111/liv.14350 · Cited by 51
Hüttl, M., Marková, I., Miklánková, D., Zapletalová, I., Poruba, M., Haluzík, M., Vaněčková, I., & Malínská, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111513 · Cited by 52
“According to recent randomized clinical studies, empagliflozin treatment ameliorates hepatic fat accumulation in diabetic subjects [7,8], with one study even noting an effect in NAFLD patients without T2DM [9].”
BackgroundThe Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients
El-Hini, S. H., Wahsh, E. A., Elberry, A. A., Ameen, N. F. E., Saedii, A. A. F., Refaie, S. M., Elsayed, A. A., & Rabea, H. (2022) · Pharmaceuticals · doi:10.3390/ph15121516 · Cited by 50
“During the study, the EMPA and UDCA groups had a significantly comparable reduction in liver enzymes and GGT.”
BackgroundMethodResultInfluentialLee, C., Seto, W., Lui, D. T. W., Fong, C. H.-Y., Wan, H. Y., Cheung, C. Y. Y., Chow, W.-S., Woo, Y. C., Yuen, M., Xu, A., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0131 · Cited by 53
SGLT2 Inhibitors in Liver Patients
Hsiang, J. C., & Wong, V. W.-S. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.05.021 · Cited by 48
Veelen, A., Andriessen, C., den Kamp, Y. J. M. O., Erazo‐Tapia, E., de Ligt, M., Mevenkamp, J., Jörgensen, J. A., Moonen‐Kornips, E., Schaart, G., ESTERLINE, R. L., et al. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155396 · Cited by 52
Veelen, A., Erazo‐Tapia, E., Oscarsson, J., & Schrauwen, P. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101158 · Cited by 53
Liver-targeting drugs and their effect on blood glucose and hepatic lipids
Gastaldelli, A., Stefan, N., & Häring, H. (2021) · Diabetologia · doi:10.1007/s00125-021-05442-2 · Cited by 49
Self-citationNascè, A., Gariani, K., Jornayvaz, F. R., & Szántó, I. (2022) · Antioxidants · doi:10.3390/antiox11061131 · Cited by 56
“SGLT-2 inhibitors were effective in reducing liver fat content but had less impact on inflammation and fibrosis, both in a murine NASH model (canagliflozin) [300] and in clinical trials (dapagliflozin and empagliflozin) [310,311].”
BackgroundMao, X., Zhang, X., Kam, L. Y., Chien, N., Lai, R., Cheung, K. S., Yuen, M., Cheung, R. C., Seto, W., & Nguyen, M. H. (2024) · Gut · doi:10.1136/gutjnl-2024-332481 · Cited by 49
“…study built on and expanded prior findings of benefits of SGLT-2i with improvement of liver enzymes and hepatic steatosis among diabetic MASLD 21–23 by applying PS matching approaches to a broad population with diabetic MASLD to provide robust data of significant and consistent risk reduction…”
NIRANJAN, S., Phillips, B. E., & Giannoukakis, N. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1193373 · Cited by 51
Mirarchi, L., Amodeo, S., Citarrella, R., Licata, A., Soresi, M., & Giannitrapani, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073668 · Cited by 44
“, [83] 2020; RCT, prospective, multi center.”
BackgroundBica, I.-C., Stoica, R. A., Salmen, T., Janež, A., Volčanšek, Š., Popovic, D. S., Muzurović, E. M., Rizzo, M., & Stoian, A. P. (2023) · Medicina · doi:10.3390/medicina59061136 · Cited by 48
Zisis, M., Chondrogianni, M. E., Ανδρουτσάκος, Θ., Rantos, I., Oikonomou, E. K., Chatzigeorgiou, A., & Kassi, E. N. (2025) · Biomolecules · doi:10.3390/biom15030324 · Cited by 48
The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease
Filipović, B. F., Lukić, S., Mijac, D. D., Marjanovic-Haljilji, M., Vojnović, M., Bogdanović, J. M., Glišić, T., Filipović, N., Kiswani, J. A., Djoković, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413219 · Cited by 46
Yoneda, M., Kobayashi, T., Honda, Y., Ogawa, Y., Kessoku, T., Imajo, K., Nogami, A., Taguri, M., Kirikoshi, H., Saito, S., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1993 · Cited by 43
Gohari, S., Ismail‐Beigi, F., Mahjani, M., Ghobadi, S., Jafari, A., Ahangar, H., & Gohari, S. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01512-1 · Cited by 39
“Three studies had used canagliflozin [22, 24, 25], 9 had used dapagliflozin [21, 26, 28–34] and 6 had used empa-gliflozin [23, 27, 35–38].”
MethodAkbari, A., Rafiee, M., Sathyapalan, T., & Sahebkar, A. (2022) · Journal of Diabetes Research · doi:10.1155/2022/7520632 · Cited by 42
Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes
Abdelgani, S., Khattab, A., Adams, J. M., Baskoy, G., Brown, M., Clarke, G., Larvenenko, O., DeFronzo, R. A., & Abdul‐Ghani, M. A. (2024) · Diabetes Care · doi:10.2337/dc23-1646 · Cited by 43
Kahl, S., Ofstad, A. P., Zinman, B., Wanner, C., Schüler, E., Sattar, N., Inzucchi, S. E., & Roden, M. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14670 · Cited by 36
“8,9 The present study examined the effects of empagliflozin treatment in a large cohort of persons with type 2 diabetes with established cardiovascular disease (a) on indices of hepatic steatosis and fibrosis, (b) on glycaemia and body weight, as well as (c) on cardiorenal outcomes and all-cause…”
BackgroundSelf-citationImpact of NAFLD and its pharmacotherapy on lipid profile and CVD
Wang, Z., Ye, M., Zhang, X., Zhang, P., Cai, J., Li, H., & She, Z. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.07.010 · Cited by 40
What’s New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
Kosmalski, M., Frankowski, R., Ziółkowska, S., Różycka-Kosmalska, M., & Pietras, T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051852 · Cited by 40
The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review
Zachou, M., Flevari, P., Ansari, N. N., Varytimiadis, C., Kalaitzakis, E., Kassi, E. N., & Ανδρουτσάκος, Θ. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03586-1 · Cited by 42
Chung, S. W., Moon, H.-S., Shin, H., Han, H., Park, S., Cho, H., Park, J., Hur, M. H., Park, M. K., Won, S., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000837 · Cited by 39
“[50] As adiponectin levels increase with the use of SGLT2i, this suggests a potential role of these inhibitors in preventing the advancement of hepatic fibrosis and preventing cancer development, including HCC.”
Buttice, L., Ghani, M., Suthakar, J., Gnanalingham, S., Carande, E. J., Kennedy, B. W. C., Pitcher, A., Gamble, J. H. P., Ahmad, M., Lewis, A., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15586 · Cited by 41
“Of the 38 trials, 17 were deemed to have ‘ low ’ risk of bias, 36,37,39,46 – 48,52,54,55,61,63,68 – 70,75 – 77 14 warranted ‘ some concern ’ 38,40,49 – 51, 56 (2/12), HOMA-IR (4/13) and TNF-α (3/5).”
Sonaglioni, A., Cerini, F., Fagiani, V., Nicolosi, G. L., Rumi, M. G., Lombardo, M., & Muti, P. C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082690 · Cited by 52
“…that the reproducibility of STE analysis may be affected by the inter-vendor variability, operator’s experience, the quality of echocardiographic images, the frame rate setting, the loading conditions and, finally, extrinsic mechanical factors, particularly anterior chest wall deformity [81–84].”
Endpoints in NASH Clinical Trials: Are We Blind in One Eye?
Lonardo, A., Ballestri, S., Mantovani, A., Targher, G., & Bril, F. (2024) · Metabolites · doi:10.3390/metabo14010040 · Cited by 37
“The evidence for SGLT2 inhibitors comes mainly from randomized, controlled trials using magnetic resonance imaging as the primary outcome [58,59].”
BackgroundMcLean, P., Bennett, J., Woods, E. A., Chandrasekhar, S. A., Newman, N. A., Mohammad, Y., Khawaja, M., Rizwan, A. M., Siddiqui, R., Birnbaum, Y., et al. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00068-z · Cited by 46
Kanwal, F., Bril, F., Wong, V. W., Adams, L. A., Pfotenhauer, K. M., SKOLNIK, N., Wright, E. E., Eckel, R. H., Noureddin, M., Loomba, R. S., et al. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.01.047 · Cited by 47
NAFLD in type 2 diabetes mellitus: Still many challenging questions
Cernea, S., & Raz, I. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3386 · Cited by 38
Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors
Yanai, H., Hakoshima, M., Adachi, H., & Katsuyama, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094416 · Cited by 35
Self-citation
Metadata
- Authors
- Kahl, S., Gancheva, S., Straßburger, K., Herder, C., Machann, J., Katsuyama, H., Kabisch, S., Henkel, E., Kopf, S., Lagerpusch, M., Kantartzis, K., Kupriyanova, Y., Markgraf, D., van Gemert, T., Knebel, B., Wolkersdorfer, M. F., Kuss, O., Hwang, J.-H., Bornstein, S. R., Kasperk, C., Stefan, N., Pfeiffer, A., Birkenfeld, A. L., & Roden, M.
- Affiliations
- Deutsches Diabetes-Zentrum e.V. (DE)
- German Center for Diabetes Research (DE)
- GWT-TUD GmbH (Germany) (DE)
- University Hospital Heidelberg (DE)
- German Center for Diabetes Research, München-Neuherberg, Germany
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich-Heine University, Düsseldorf, Germany
- Landesapotheke Salzburg, Salzburg, Austria
- Paul Langerhans Institute Dresden (DE)
- Corresponding author
- Roden, Michael
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-09-20
- Volume
- 43
- Issue
- 2
- Pages
- 298-305
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2973671909
- Semantic Scholar
- d30e2aeb028f87844806b2c67eeca77b51e7e36a
- Cited by
- 360
- References
- 43
- Citations by year
- 2026: 47 · 2025: 59 · 2024: 58 · 2023: 59 · 2022: 54 · 2021: 46 · 2020: 35 · 2019: 1
- FWCI
- 27.61
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Site cant be reached (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- German Diabetes Center
- German Federal Ministry of Health
- German Center for Diabetes Research
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- empagliflozin, SGLT2 inhibitors, type 2 diabetes, liver fat, hepatic steatosis, non-alcoholic fatty liver disease, insulin sensitivity, uric acid, high molecular weight adiponectin, weight loss, glycemic control, recent-onset diabetes, isotope dilution
- MeSH terms
- Adipose Tissue, Aged, Benzhydryl Compounds, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Germany, Glucosides, Humans, Hypoglycemic Agents, Insulin Resistance, Liver, Male, Middle Aged, Placebos, Weight Loss, Down-Regulation, Adiposity, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.